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To examine if uremia influences muscle interleukin-6 (IL-6)
metabolism we studied the exchange of IL-6 across the
forearm in 16 patients with chronic kidney disease (CKD)
(stages 3 and 4), in 15 hemodialysis (HD)-treated end-stage
renal disease (ESRD) patients (n¼ 15), and in six healthy
controls. In addition, we performed an analysis of both IL-6
protein and IL-6 mRNA expression in muscle of CKD (stage 4)
patients showing evidence of inflammation and in controls. A
release of IL-6 from the forearm was observed in patients
with elevated IL-6 plasma levels. Arterial IL-6 was directly
related to released IL-6 (r¼ 0.69; Po0.004) in HD patients.
Both IL-6 protein and IL-6 mRNA expression were increased
in muscle of inflamed CKD patients vs controls (Po0.05).
Although muscle net protein balance was similar in all
patients, it was significantly more negative in HD patients
with high than in those with low IL-6 plasma levels (Po0.05).
In addition, net protein balance was related to the forearm
release of IL-6 in HD patients only (r¼ 0.47; Po0.038). These
data demonstrate that IL-6 expression is upregulated in
muscle, and that muscle tissue, by releasing this cytokine,
may contribute to the inflammatory response in HD patients.
The release of IL-6 from peripheral tissues is associated with
an increase in muscle protein loss in HD patients, suggesting
that muscle release of IL-6 is linked to protein catabolism in
these patients. The release of IL-6 from peripheral tissues
may act as a signal for the inflammatory response and
contribute to functional dysregulation in uremia.
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Several studies have shown a strong association between
chronic inflammation and long-term mortality and morbid-
ity in patients with end-stage renal disease (ESRD).1,2 The
percentage of patients showing evidence of inflammation
increases progressively along with the decline in renal
function, suggesting that cell release and/or body removal
of pro-inflammatory cytokines is altered by uremia.3
Interleukin-6 (IL-6) is a major factor coordinating the
acute-phase response4 and plasma levels of IL-6 are
associated with increased cardiovascular risk5 and loss of
muscle mass,6 both in the general population and in ESRD
patients.7 However, sites and mechanisms responsible for the
regulation of circulating IL-6 and other cytokines in humans
are currently poorly known. Although most of the circulating
IL-6 is secreted from activated macrophages and lympho-
cytes, adipocytes8 and skeletal muscle9 are also a possible
source of this cytokine. IL-6 mRNA is expressed in resting
human muscle and is rapidly increased by contraction.9 A
release of IL-6 from the legs (which are mainly composed of
skeletal muscle) has been shown to take place during physical
exercise or glycogen depletion.9,10 In addition, it has been
recently observed that insulin increases IL-6 gene expression
in insulin-resistant, but not in healthy skeletal muscle11 and
that IL-6 is released by the forearm muscle in obese
subjects.12 Both reactive oxygen species9,10 and lipopolysac-
charide9,10 can upregulate muscle IL-6, likely because of an
activation of nuclear factor, nuclear factor-kB. Muscle-
derived IL-6 could play a physiological role to maintain
metabolic homeostasis by stimulating lipolysis during
periods of increased metabolic demand. In addition, in the
context of skeletal muscle, IL-6 has variously been reported to
regulate carbohydrate metabolism, increase satellite cell pro-
liferation, or cause muscle wasting.11–14 Therefore, available
data indicate that several physiologic and pathological stimuli
are able to prime the mechanisms for muscle IL-6 release.
Whether uremia induces changes in muscle IL-6 metabo-
lism has never been examined. The aim of the present study
was to explore the hypothesis that IL-6 could be locally
produced in skeletal muscle and exported to other tissues.
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First, we studied the exchange of this cytokine across the
forearm (which is mainly made of skeletal muscle) in patients
with chronic kidney disease (CKD) (stages 3 and 4) and in
hemodialysis (HD) patients. In addition, in order to further
explore whether muscle cells per se are the source of the
elevation in IL-6, we performed an analysis of both IL-6
protein (by immunohistochemistry) and IL-6 mRNA expres-
sions in muscles of patients with severe chronic renal failure
showing evidence of inflammation.
RESULTS
IL-6 balance across peripheral tissues
Plasma flow across the forearm was 1.970.13, 2.270.15,
and 2.270.30 ml/min/100 ml, respectively, in CKD, ESRD
patients, and control subjects (P¼NS).
Individual arterial and venous levels of IL-6, as well as
their exchange rates across the forearm are reported in
Table 1. Arterial levels of IL-6 in controls were within the
range of those previously reported in arterial plasma.15 In
addition, IL-6 levels in the deep forearm vein, although
tendentiously higher, were not statistically different from
their corresponding arterial level. Similar findings have been
obtained across the forearm8 and the leg12 in healthy subjects.
Arterial IL-6 levels were 45 pg/ml in seven CKD and 10
ESRD patients. In these patients, the deep venous IL-6 levels
were significantly higher than the corresponding value in the
artery (Table 2). A release from peripheral tissues was
observed only as a trend in CKD patients who showed IL-6
levels o5 pg/ml. When considered as a whole group, the
negative arterio-venous difference for IL-6 was statistically
significant (Po0.008) in CKD and ESRD patients. The
release of IL-6 from peripheral tissues was about sevenfold
increased in HD patients with high IL-6 vs the corresponding
value in CKD patients. Arterial IL-6 was directly related to
peripheral release of IL-6 in HD patients (r¼ 0.69; Po0.004)
(Figure 1a), suggesting that release from periphery can
influence plasma IL-6 levels. However, this association was
not statistically significant in CKD patients (r¼ 0.331;
P¼NS) (Figure 1b).
Cytokine arterial plasma levels were greater in patients
with CKD than in controls (IL-1b¼ 6.571.9, IL-10¼ 2.77
0.2, and tumor necrosis factor-a¼ 33.073.2 pg/ml in
patients vs IL-1b¼ 3.071, IL-10¼ 1.770.2, and tumor
necrosis factor-a¼ 11.572 pg/ml in controls, Po0.05–
0.01). Plasma levels of these cytokines tended to be further
increased in HD patients (IL-1b¼ 9.372.0, IL-10¼ 5.870.3,
and tumor necrosis factor-a¼ 93712 pg/ml, Po0.05-0.01 vs
controls). However, no significant arterio-venous gradient
across the forearm was observed for these cytokines both in
control subjects and each patient category (data not
reported).
The evaluation of cardiovascular profile yielded a
cardiovascular score higher in inflamed vs non-inflamed
HD patients (3.7870.32 vs 270.6, Po0.02). Conversely, this
score was similar in inflamed vs non-inflamed CKD subjects
(2.070.32 vs 2.070.29). The release of IL-6 from the
forearm was linearly, directly related to the cardiovascular
Table 1 | Forearm exchange of interleukin-6 in patients in controls
Artery (pg/ml) Forearm vein (pg/ml) AV difference Rate (pg/min 100 ml)
Controls (n=6) 3.270.98 3.570.99 0.270.20 0.570.4
CKD (IL6 45 pg/ml, n=7) 28.876.2d,e,f 29.676.26a 0.870.33 1.570.49
CKD (IL6o5 pg/ml, n=9) 2.570.48 2.870.54 0.370.25 0.970.45
CKD (all subjects, n=16) 14.074.26 14.574.31a 0.570.17 1.1270.28
ESRD (IL645 pg/ml, n=10) 44.177.36d,e 49.678.54b 5.571.82 11.173.40d,h
ESRD (IL6o5 pg/ml, n=5) 3.3070.58 3.3470.56 070.03 070.75
ESRD (all subjects, n=15) 30.577.05d 34.478.08c 3.771.38 7.472.66g
Data are expressed as mean7s.e.m. Significance of difference of arterial (A) vs venous (V) concentration: aPo0.05, bPo0.035, cPo0.02.
Significance of difference vs controls: dPo0.05 or less. Significance of difference vs the corresponding value in patients with low IL-6: ePo0.01. Significance of difference vs
the corresponding value in ESRD patients with low IL-6: fPo0.001. Significance of difference vs the corresponding value in CKD (all subjects): gPo0.05. Significance of
difference vs the corresponding value in CKD patients with high IL-6: hPo0.05.CKD, chronic kidney disease; ESRD, end-stage renal disease; IL-6, interleukin-6.
Table 2 | Characteristics of the patients
Forearm
balance study
(CKD
patients)
Forearm
balance study
(HD patients)
Muscle
biopsy study
(CKD
patients)
Gender (M/F) 13M/3F 12M/3F 7M/8F
Age (years) 6672 6773 6973
Body weight (kg) 7374 6874 6774
Height (cm) 16973 16873 16372
BMI (kg/m2) 2671 2471 2571
Fat-free mass (kg) 4972 467 8 4572
Fat mass (kg) 2572 2172 2273
nPNA (g/kg) 0.9070.1 170.1 0.8570.1
Estimated GFR
(ml/min.1.73 m2)
2472 271b,c 8.471b
Serum creatinine (mg/dl) 3.070.2 1071b,c 6.870.4b
Serum albumin (g/dl) 3.570.03 3.470.13 3.570.2
BUN (mg/dl) 6175 8478a 8473 a
Bicarbonate (mmol/l) 23.170.50 22.070.90 23.270.9
CRP (mg/l) 1273 3578a 2878
Hemoglobin (g/dl) 1271 10.571 11.370.3
Cardiovascular scored 2.0870.23 2.9470.35 2.1370.46
BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; CRP,
C-reactive protein; F, Female; HD, hemodialysis; M, male; nPNA, normalized protein
nitrogen appearance; GFR, glomerular filtration rate. Significance of difference vs the
forearm balance study: aPo0.05; bPo0.001. Data are expressed as mean7s.e.m.
Significance of difference vs the muscle biopsy study: cPo0.05. Cardiovascular score
was obtained by the use of a standardized four-level scale based on atherosclerotic
events.25
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score in HD (r¼ 0.603; Po0.003), but not in CKD patients
(r¼ 0.08; P¼NS).
C-reactive protein (CRP) levels correlated directly with
forearm release of IL-6 (r¼ 0.72; Po0.001). However, when
patients were considered separately, this association persisted
to be statistically significant in HD patients only (HD
patients r¼ 0.70, Po0.002; CKD patients, r¼ 0.24, P¼NS).
No relationship was observed between indexes of obesity
(body mass index and body fat mass), plasma bicarbonate,
hemoglobin, uric acid, residual renal function, and the
release of IL-6 from the forearm.
Net protein balance across the forearm
Both in patients and controls, the deep venous phenylalanine
levels exceeded the arterial ones (Po0.01), thus indicating
phenylalanine release from the forearm and proteolysis. Net
phenylalanine balance across the forearm in CKD and in
dialyzed ESRD patients was similar to controls (Figure 2).
When considering CKD patients separately according to IL-6
levels, net protein balance was also not different in patients
with high vs low plasma IL-6. However, net phenylalanine
balance was significantly more negative (indicating a decrease
in muscle protein synthesis or an increase in protein
degradation) in HD patients showing evidence of microin-
flammation as compared to non-inflamed HD subjects. Net
phenylalanine balance was weakly related to IL-6 release from
the forearm when considering together CKD and ESRD
patients (r¼ 0.365; Po0.1). However, a significant relation
between forearm phenylalanine and IL-6 release was again
observed in HD but not in CKD patients (r¼ 0.469,
Po0.037) (Figure 3a and b).
Muscle biopsy studies
Patients studied in this group displayed evidence of an
inflammatory response (plasma CRP 2875 mg/dl; IL-6
1572 pg/ml). As Figure 4 shows, we were able to detect
IL-6 mRNA in muscles, both in patients and in controls.
Muscle IL-6 mRNA was, however, 2.4-fold increased
(Po0.05) in patients vs controls.
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Figure 1 | Relationship between arterial IL-6 and its release from
peripheral tissues (a) in HD-treated patients with ESRD or (b)
with CKD (stages 3 and 4). Arterial IL-6 levels were related to the
release of IL-6 from peripheral tissues in HD patients, but not in CKD
patients.
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Figure 2 | Net protein balance across the forearm in the post-
absorptive, basal state in patients with CKD (stages 3 and 4) and
in HD-treated patients with ESRD. Data are expressed as
mean7s.e.m. *Po0.05 vs HD patients without inflammatory
response.
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Figure 3 | Relationship between the release of phenylalanine and
that of IL-6 from peripheral tissues (a) in HD-treated patients
with ESRD and (b) in patients with CKD (stages 3 and 4). The
release of phenylalanine by peripheral tissues increased progressively
along with the release of IL-6. This correlation was observed in HD,
but not in CKD patients.
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The IL-6 staining was absent in muscle tissue from healthy
subjects. Representative images are shown (Figure 5a and b)
for one control subject and three CKD patients. In CKD
patients, the expression of IL-6 was clearly detectable (Figures
5 and 6). The IL-6 staining appeared as a diffuse staining of
the cytoplasm of skeletal muscle fibers in all subjects. There
was no IL-6 staining present between muscle fibers. In
addition, mononuclear infiltrates were negative for IL-6
immunostaining.
DISCUSSION
In the present study, we tested the hypothesis that IL-6, a
major mediator of the acute-phase response, is released by
skeletal muscle both in patients with moderate advanced
CKD and those with ESRD displaying evidence of an
inflammatory response. This issue has been assessed by
multiple determinations, including the measure of IL-6
balance across the forearm (which is mainly made of skeletal
muscle), immunohistochemical evaluation of IL-6 in muscle,
and muscle detection of IL-6 mRNA. First, we observed that
IL-6 is released by peripheral tissues into the systemic
circulation in patients with evidence of inflammation. On the
contrary, no significant gradient of IL-6 occurs across
peripheral tissues both in healthy controls and patients
without evidence of an inflammatory response. In addition,
we observed that IL-6 gene and protein expression are
upregulated in skeletal muscle of patients with advanced
CKD displaying an inflammatory response. Accordingly, the
peripheral output of IL-6 in uremia can be attributed to an
increase in IL-6 gene transcription within skeletal muscle and
translation of IL-6 protein that is subsequently released.
Our IL-6 tissue immunohistochemical findings in uremic
patients are similar to those reported by Febbraio et al.,9 who
showed that IL-6 protein was distributed homogenously
across muscle fibers in exercising healthy subjects. In our
study, although only scanty mononuclear infiltrates were
observed across muscle fibers in CKD patients, these were
negative for IL-6 immunostaining (Figure 5). These con-
siderations suggest that IL-6 is directly produced by muscle
cells.
Recently, it has been estimated that 10–35% of the body’s
basal circulating IL-6 is derived from adipose tissue.16
According to our data, the output of IL-6 from peripheral
tissues can play a major role in influencing circulating levels
of this cytokine in patients with CKD. Results obtained in
healthy subjects that no significant enrichment or depletion
of IL-6 occurs across the forearm muscle are in accordance
with previous findings obtained across the forearm8 and leg17
in the normal condition. The released IL-6 output from the
forearm observed in CKD patients is of the same magnitude
observed recently in obese, insulin-resistan subjects.12
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Figure 4 | IL-6 mRNA expression is increased in uremic muscle.
Total RNA was extracted from Rectus Abdominis muscles of control
and CKD patients. Semiquantitative PCR was performed for IL-6 and
b-actin (see Materials and methods). Representative reverse tran-
scriptase-PCR analysis of skeletal muscle IL-6 and b-actin messages in
four consecutive patients and controls (a). Densitometric values for
IL-6 mRNA were normalized for b-actin expression, and the ratio of
IL-6 to b-actin was determined (b). Values are means7s.e.m.
*Significantly different (Po0.05) vs controls
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Figure 5 | IL-6 expression (immunostaining) is increased in uremic
muscle. Immunohistochemical analysis was performed with an
anti-human IL-6 polyclonal antibody in Rectus Abdominis muscles
of control and CKD patients. IL-6 protein was visualized by
image analysis. Control subject (a) and patients with CKD and
microinflammation (b, c, d). (original magnification  1000).
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Figure 6 | Results of IL-6 image analysis (immunostaining) in
patients with CKD (n¼ 10) and controls (n¼ 6) in the resting
state. Values are means7s.e.m. *Significantly different (Po0.05) vs
controls.
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According to the measure of the forearm arterio-venous
gradient of IL-6 in obese subjects, the estimated contribution
of IL-6 release from skeletal muscle to systemic IL-6 is about
12%, varying from 2 to 42%.12 In our study, we observed that
the IL-6 output was fairly matched by variations in arterial
levels of the same cytokine in HD, but not in CKD patients.
The correlation coefficient of the relation is 0.69, indicating
that about 48% of variations in arterial IL-6 were explained
by variations in IL-6 release from periphery in HD subjects.
According to the measurement errors in each variable, this
indicates a strong association, and suggests that release by
muscle plays a major role in determining IL-6 plasma levels
in HD patients. The reason(s) why such an association was
not found in patients with less-advanced renal disease may
include on one hand, the residual metabolic activity of the
kidney, which can remove IL-6 from blood (unpublished data
from our laboratory), and, on the other hand, a more marked
inflammatory condition in hemodialysis-treated patients.
Which signals might trigger IL-6 release from muscle in
uremia? Several upstream factors have been shown to be able
to induce the transcription of this cytokine in human muscle
in vitro or in vivo. IL-6 synthesis is activated by intracellular
calcium levels, mitogen-activated protein kinases, and other
cytokines such as IL-1b.9 Nutritional factors, such as low
glycogen availability, can also increase IL-6 transcription.17
Of note, the uptake of glucose by skeletal muscle is blunted18
and muscle glycogen depletion have been reported by some
studies in uremic patients. In addition, reactive oxygen
species can upregulate muscle IL-6, likely because of an
activation of nuclear factor, nuclear factor-kB.9,10,19
Another possible signal is related to metabolic acidosis.
Metabolic acidosis contributes to the regulation of synthesis
of inflammatory cytokines in circulating cells, and, possibly,
in skeletal muscle.20,21 In this regard, we were not able to find
a relation between bicarbonate levels and forearm release of
IL-6. However, most of the patients in our study displayed
bicarbonate levels in the normal range.
We conclude that IL-6 expression is upregulated in
muscle, and that forearm muscle releases substantial amounts
of IL-6, a major mediator of the acute-phase response, in
patients with CKD or ESRD and with evidence of
inflammation. The relation between arterial IL-6 and CRP
levels suggests that release of this cytokine from periphery
may act as a signal for the inflammatory response. However,
the biological effects of muscle-derived IL-6 in physiological
and pathologic states are not completely ascertained. IL-6
released from muscle might behave as a hormone to increase
substrate delivery.8 One of the effects of IL-6 is to stimulate
lipolysis, causing the release of NEFA from the adipocyte.
This effect may be beneficial to sustain body needs during
exercise, but could be harmful in chronic illness conditions.22
In addition, IL-6 might behave on skeletal muscle as an
autocrine factor. Elevated levels of IL-6 are associated with a
reduction in muscle mass and muscle strength23 When
administered to animals, IL-6 can cause muscle atrophy with
changes in the balance of growth-factor-related signaling
favoring a catabolic profile.13 If so, peripheral tissues could
play a double role of victim and culprit of the inflammatory
response in uremia. In our study, net protein balance across
peripheral tissues was greater in inflamed vs non-inflamed
HD patients. In addition, the release of IL-6 correlated with
the negative protein balance in HD but not in CKD patients.
This indicates that inflammation may affect the control of
protein balance in HD patients, by acting either directly or
indirectly, on protein synthesis and/or degradation. It is of
note that such a relation was not observed in CKD patients,
even in those displaying an inflammatory response. It is
unclear if this was due to a lower degree of inflammation in
this patients subgroup or to catabolic mechanisms specifi-
cally activated in HD-treated patients. With this regard, it is
interesting that it has been recently observed that hemo-
dialysis acutely increases IL-6 gene expression in skeletal
muscle.24 Taken together, our data show that the effects of
muscle-derived IL-6 on protein metabolism, as well as its
endocrine/autocrine effects should be fully explored in renal
patients as well as in other chronic conditions. Under-
standing these processes should allow for a new therapeutic
approach to uremia and its complications.
MATERIALS AND METHODS
Forearm exchange of cytokines
Thirty-one patients with CKD participated in this study (Table 2).
Patients had no evidence of gastrointestinal or liver disease,
malignancy, or intercurrent infection. Sixteen patients had moderate
to severe CKD with estimated25 glomerular filtration rate of
2472 ml/min (range 13–38); their systolic and diastolic arterial
pressures were 150711 and 8879 mm Hg, respectively. Fifteen were
maintenance HD patients (mean dialytic age 27 months, range 6–72;
Kt/V 1.3570.1). Their systolic and diastolic arterial pressure were
155712 and 9077 mm Hg, respectively. Causes of renal diseases
were glomerulonephritis (10 patients), hypertensive nephrosclerosis
(15 patients), tubulointerstitial nephritis (three patients), type II
diabetic nephropathy (two patients), and polycystic renal disease
(one patient). Patients were taking drugs, including antihypertensive
drugs, sodium bicarbonate, calcium carbonate, and erythropoietin,
which were prescribed as appropriate for each individual. An
increase in CRP levels (410 mg/l) and signs of cardiovascular
disease (coronary artery disease or peripheral artery disease) were
present in seven patients with CKD and 10 patients with ESRD.
Cardiovascular profiles in each patient were evaluated by a
standardized scale based on atherosclerotic events (coronary heart
disease, cerebrovascular disease, and peripheral vascular disease).25
Three of the CKD and six of the ESRD patients were moderately
malnourished according to subjective global nutrition assessment.
Estimated calorie intake was 30–32 and 28–32 kcal/kg, respectively, in
CKD and ESRD patients, respectively.
Control subjects (4M/2F, age 6176 years, body mass index
2474 g/m2) were on a diet providing 31–35 kcal and 1–1.2 g of
protein/kg/day. Routine laboratory tests, acid–base and electrolyte
measurements were all normal.
The study was part of a larger protocol on protein metabolism in
CKD approved by the Ethical Committee of the Department
of Internal Medicine of the University of Genoa. All subjects
were informed about the nature, purposes, procedures, and
possible risks of the study before their informed consent was
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obtained. The procedures were in accordance with the Helsinki
declaration.
Protocol
Patients were studied in the post-absorptive state, at rest. To avoid
possible interferences of the dialytic procedure, HD patients were
studied after approximately 72–74 h from the last dialytic treatment.
Catheters were placed percutaneously into a brachial artery and an
ipsilateral retrograde cubital vein. After a 30-min period, triplicate
sets of arterial and venous samples were taken at 20-min intervals
during a 60-min period. The oxygen saturation in the forearm
venous samples was less than 60%, implying that deep venous blood
was actually sampled. Forearm blood flow was measured by strain-
gauge plethysmography.26,27 Flow was expressed per 100 ml forearm
volume.
Blood was collected in (ethylenediaminetetraacetic acid) tubes,
which were immediately centrifuged at 6000 r.p.m. for 10 min at
þ 41C. Plasma was quickly separated from blood cells and stored at
801C until assayed. Plasma IL-6 concentrations were determined
by a high sensitivity human IL-6 enzyme-linked immunosorbent
assay technique (Diaclone, Besancon, France). IL-1, IL-10, and
tumor necrosis factor-a were also measured in plasma using
enzyme-linked immunosorbent assay kits (Diaclone, Besancon,
France) according to the manufacturer’s directions. Assays were
performed in triplicate. The inter- and intra-assay coefficient of
variance % for each cytokine were o5%. In particular, the IL-6
assay had a limit of detection of 0.8 pg/m, intra-assay coefficient of
variance of 2.8%, and interassay coefficient of variance of 1.4%. All
samples from one individual were always run in the same batch.
Samples in the high range (450 pg/ml) were appropriately diluted.
Net protein balance across the forearm was measured from the
release of phenylalanine.27 Net protein balance represents the
difference between protein synthesis and degradation. In the
postabsorptive condition, as evaluated in the present study, the
net balance of phenylalanine across the forearm is negative because
protein degradation is greater than protein synthesis.
Hematocrit was measured by a microcapillary procedure and
serum CRP by nephelometry.
Calculations
The exchange of IL-6 and phenylalanine across the forearm was
calculated by the Fick’s principle: ((Xa)–(Xv)) plasma flow, where
Xa and Xv are the concentrations of the metabolites in arterial and
venous plasma, respectively. A cutoff value of 5 pg/ml was employed
to separate patients with high or normal IL-6 values.15
Body composition was estimated by anthropometry.28 Plasma
flow was calculated from blood flow and hematocrit.
Studies on muscle biopsies
Muscle biopsies were obtained from Rectus Abdominis muscle of 15
ESRD patients (seven males, eight females) during the placement of
a peritoneal dialysis catheter. Samples were taken in 12 otherwise
healthy subjects (7M/5F, age 6674 years) from the rectus abdominis
muscle during elective surgery for abdominal wall hernias
(controls). Both these procedures were performed under local
anesthesia. Clinical characteristics of patients are shown in Table 2.
Causes of renal diseases were hypertensive nephrosclerosis (10
patients), chronic glomerulonephritis (two patients), tubulointer-
stitial nephritis (two patients), and obstructive uropathy (one
patients). All patients presented an increase in CRP levels. Two
patients had isolated monolateral and 10 bilateral peripheral arterial
disease. Coronary artery disease was observed in four patients.
Immediately following each biopsy, muscle tissue was separated into
two sections: one of these was used for RNA analysis and the other
mounted in TissueTek (Fronine, Riverstone, Australia), frozen in
isopentane (BDH Laboratory Supplies, Poole, UK) over liquid
nitrogen, and stored at 801C until later analysis.
Histological preparation and immunohistochemical staining
for human IL-6 protein
Paraffin sections (5mm) of 2% paraformaldeyde-fixed muscle (10
ESRD patients and six control subjects) were deparaffined, hydrated,
and pretreated with pepsin for 15 min at 371C and 0.01% NP-40 for
30 min. Samples were treated with 3% H2O2 in methanol for 15 min.
Sections were incubated in primary antibody (1:200 in phosphate-
buffer saline) (anti-human IL-6, rabbit polyclonal antibody, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight at room
temperature. Subsequently, sections were incubated with the
secondary antibody (biotynilated immunoglobulin G 1:100 in
phosphate-buffer saline) for 30 min. The biotin–streptavidin–peroxi-
dase method and light microscopy examination were performed as
previously decribed.29
Measurement of IL-6 mRNA in muscle biopsies by reverse
transcriptase-polymerase chain reaction
Total RNA was extracted by applying Trizol reagent (Invitrogen,
Milan, Italy). Subsequently, the homogenized samples were
incubated at room temperature for 15 min. Chloroform (0.2 ml/
ml) was added to the solution and the total RNA was precipitated
from the aqueous phase by adding isopropanol and incubated for
15 min at room temperature. This operation was followed by
centrifugation for 15 min at 12 000 g at 41C. After a rinse in 75%
ETOH, the final pellets were re-suspended in 30/50ml of nuclease-
free water.
To check the quality of the RNA, sample aliquots were separated
by agarose gel electrophoresis and visualized by ethidium bromide
staining. The quantity of extracted RNA was measured spectro-
photometrically at 260 nm. Complementary DNA (cDNA) was
reverse transcribed (reverse transcriptase) from 0.5/1 mg of total
RNA using 20 pmol/ml random hexamers and 5 U Improm II
Reverse transcriptase (Promega Corp. Madison, WI, USA) in a final
volume of 20 ml. To test the reverse transcriptase, the samples were
amplified for a housekeeping gene, the b-actin. cDNA was amplified
by polymerase chain reaction (PCR) reaction in a total volume of
25 ml of reaction mixture containing 1 PCR buffer with MgCl2
(Eppendorf, Hamburg, Germany), 0.2 mM each of dATP, dTTP,
dCTP, dGTP, 0.25 mM of forward and reverse primers (gene of
interest), and 0.5 U of Taq DNA polymerase (Eppendorf, Hamburg,
Germany). Amplification products were subjected to electrophoresis
through 1.5% agarose gels, purified with a DNA gel extraction kit
(Qiaex-II,Qiagen, Milan, Italy), and used for sequence analysis.
Genomic DNA and cDNAs were sequenced in an automatic
sequencer.
PCR was performed in a Peltier Thermal Cycler dual block
(PTC100 MJ, GMI, Ramsey, MN, USA) by use of the general cycle
profile: 951C for 5 min, as an initial denaturation, followed by 35
cycles of denaturation at 941C for 45 s, specific annealing for gene of
interest for 45 s, and extension at 721C for 1 min, with a final
extension at 721C for 10 min.
The primers were designed from human IL-6 and b-actin mRNA
sequence.30,31 A 295-bp IL-6 gene fragment was amplified using
the forward primer 50-aaattcggtacatcctcgac-30 and reverse primer
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30-caggaactggatcaggactt-50(Invitrogen, Milan, Italy). A 219-bp
b-actin gene fragment was amplified using the forward primer
50-cccaaggccaaccgcgagaagat-30 and reverse primer 30-gtcccggccagc
caggtccag-50(Invitrogen, Milan, Italy). PCR products were separated
by gel (1.5% agarose) electrophoresis, stained with ethidium
bromide and visualized by ultraviolet illumination. Relative cytokine
expression was determined in different samples, by comparing in-
sample ratios (R) of the level of cytokine relative to the level of
housekeeping gene.
Statistical analysis
The data regarding arterial and venous plasma IL-6, IL-6 mRNA,
and b-actin were normally distributed. Statistical analysis was
performed using analysis of variance for repeated measures to
compare arterial with venous data. One-way analysis of variance
followed by post hoc analysis was used to compare data from
different groups. Linear regression and correlation were employed to
evaluate the relationship between two variables. A P-value of o0.05
was considered statistically significant. Data are expressed as
mean7s.e.m.
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